Barclays’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Barclays’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85K	Sell	1,052 -804	-43%	-$1.29K	﹤0.01%	4883
2026 Q1	$3.25K	Buy	1,856 +1,478	+391%	+$4.2K	﹤0.01%	4814
2025 Q4	$769	Buy	+378	New	+$1.75K	﹤0.01%	5086

Other funds holding SXTP

KCM

Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Barclays's SXTP Position: Q2 2026 in Review

Barclays reduced its 60 Degrees Pharmaceuticals (SXTP) stake by 43% in Q2 2026, selling an estimated $1.29K and leaving 1,052 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4883.

Barclays first reported a position in SXTP in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.25K in Q1 2026. 8 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

Barclays held 1,052 shares of 60 Degrees Pharmaceuticals worth $1.85K as of Q2 2026.
Barclays sold 804 60 Degrees Pharmaceuticals shares in Q2 2026, an estimated $1.29K.
60 Degrees Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4883 holding.
Barclays first reported a position in 60 Degrees Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
Barclays's 60 Degrees Pharmaceuticals position peaked at $3.25K in Q1 2026.
8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.